Introduction: Addressing challenges in multiple myeloma management in an era of new therapeutics

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Hematologists, oncologists, and other physicians can expect to encounter an increasing number of patients with multiple myeloma. Historically, multiple myeloma has been a difficult and frustrating disease, but since the reintroduction of thalidomide and the development of lenalidomide and bortezomib, outcomes have improved considerably. This supplement is part of a 3-supplement series planned at a roundtable discussion held in 2009, and this introduction discusses the articles in this supplement as well as those in earlier and later planned publications not included in JNCCN.

Original languageEnglish
Pages (from-to)S1-S3
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume8
Issue numberSUPPL. 1
DOIs
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

Dive into the research topics of 'Introduction: Addressing challenges in multiple myeloma management in an era of new therapeutics'. Together they form a unique fingerprint.

Cite this